Unicorn Aim Vct Share Discussion Threads

[toffeeman] 17/3/2022 14:12

Just bought some of the new issue and with VCT relief my entry price is 138. Now need to leave it alone for 5 years :)

[gbcol] 10/2/2022 14:32

Yes very nice divi. Shame Avacta have continued to tank as that will have a detrimental effect on our NAV - in fact no doubt is a big reason for recent falls in NAV. Was a great run from late 2020 though.

[phillis] 10/2/2022 14:15

Ching ching!

[sphere25] 08/12/2021 17:11

This is topical:

" Largest Detractors

Avacta Group (-GBP1.6 million) is a clinical stage biopharmaceutical specialist and a developer of diagnostics tools based on innovative and proprietary Affimer(R) and pre|CISION(TM) platforms. At the end of September, Avacta released interim results, which confirmed that the business continues to struggle to achieve widespread commercial adoption of its high quality Lateral Flow Tests. Financial results were therefore below original expectations and Avacta's share price has been under considerable pressure as a result.

Omega Diagnostics (-GBP1.2 million) is a business focused on providing specialist products to immunoassay, in-vitro diagnostics (IVD) market within the Health & Wellbeing sector. During the year, Omega released results for its financial year ended 31 March 2021. Because of the severe disruption caused by the pandemic, revenues did not grow as quickly as originally anticipated and the share price has suffered accordingly.

Abingdon Health (-GBP1.1 million) is a developer and manufacturer of high-quality rapid lateral flow tests. Unfortunately, throughout the year under review, Abingdon has been embroiled in a commercial dispute with the Department of Health and Social Care (DHSC), which translated into significantly lower than expected demand for its AbC-19 rapid antibody testing product. In addition, the DHSC continues to withhold payments due to Abingdon that amount to GBP6.7 million. This dispute remains unresolved, despite Abingdon's insistence that the contract was delivered to the DHSC on time, on budget and in full. As a result, Abingdon has failed to meet growth expectations in the twelve months since its initial listing on the FTSE AIM All-Share Index.

Genedrive (-GBP0.9 million) is a molecular diagnostics company that develops and commercialises low cost, rapid, versatile, and simple to use testing platforms for the diagnosis of infectious diseases. In its half yearly report, covering the six months to 31 December 2020, Genedrive was only able to generate nominal revenues as Covid-19 headwinds continued to impact its commercial operations. In September 2021, Genedrive raised GBP6 million in additional capital in order to fund the launch of a point-of-care (POC) antibiotic induced hearing loss (AIHL) test and complete the development of its molecular Covid-19 test. "

Should be interesting to see how they all fare next year!

[sharesoc] 17/1/2018 12:56

There is a detailed report on Unicorn's recent AGM which can be found in our members area here:

To access the report, you'll need to be a full member of ShareSoc, which is a not-for-profit organisation that supports individual shareholders and campaigns for shareholder rights. If you're not already a member you can join here:

Once you've joined, you'll receive an invitation to register for our "members network" private social network, from where you'll be able to access the report (and reports on 100s of other meetings). If you're already a member and have any difficulty accessing the report, please do not hesitate to contact us here:

[ganthorpe] 12/9/2017 11:42

I prefer to buy in the Market at 143P than be ripped off at 168P with new shares. I know you get 30% of the cost back in tax relief but it still rankles.
I still get the dividends tax free , and I don't have restrictions on selling and only a 2p spread

[steve3sandal] 08/8/2017 22:15

Mf, I tend to agree about the discount here. Some of my other Aim VCTs are quite active in managing the discount c 5%. I take the view that over the next 5 years Unicorn will become more active here and if not we will ask some questions. Topped up again recently. Amongst AIM VCTs I hold Hargreaves Hale, Octopus, Amati, and feel the need to cover the field.

[rahosi] 08/8/2017 08:51

One doesn't plan to actually sell most VCTs in the market. Exit is via dividends, tenders or planned winding ups.I tend to reinvest such proceeds back into new VCTs; on and on and on.....

[mad foetus] 01/8/2017 07:57

I'm tempted, though don't like the discount to NAV it trades at. Surely you out in £1,000 and it instantly becomes £850, wiping out half the upfront tax advantage. But I'm still tempted!

[darrenp746] 01/8/2017 00:30

Anyone else investing into this. Think it's a great place to put some cash for 5 or 6 years.

[davebowler] 24/7/2017 11:23

!FOLLOWFEED